Acute respiratory distress syndrome natural history, complications, and prognosis: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
(50 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
{{Acute respiratory distress syndrome}}
{{Acute respiratory distress syndrome}}
{{CMG}}, {{AE}} {{BShaller}}
{{CMG}}; {{AE}} {{BShaller}}


==Overview==
==Overview==
ARDS usually develops within 24 to 48 hours of the initial [[injury]] or [[illness]] and typically progresses over the course of 1 to 2 weeks (refer to [[Acute respiratory distress syndrome pathophysiology|'''Pathophysiology of ARDS''']). Failure to diagnose and treat ARDS early on is associated with a high [[mortality rate]] and may result in lifelong [[complications]] among survivors.
If left untreated, 70% of patients with ARDS may progress to [[mortality]]. Common complications to ARDS include [[weakness]], impaired [[spirometry|lung function]], and [[brain death]]. Prognosis for patients with ARDS is generally poor and varies based on the severity of illness, the precipitating insult, and medical comorbidities.


==Natural History==
==Natural History==
The first signs of ARDS typically present within 24 to 48 hours of the precipitating [[illness]] or [[injury]] and progress over the course of 1 to 2 weeks. The early clinical features of ARDS include:
The natural history of ARDS is hallmarked by three histopathological phases—exudative, proliferative, and fibrotic phase—each correlated to distinctive clinical manifestations.<ref>Ware, Lorraine B. “Autopsy in ARDS: Insights into Natural History.” The Lancet. Respiratory Medicine 1, no. 5 (July 2013): 352–54. doi:10.1016/S2213-2600(13)70093-6.</ref>
*[[Hypoxemia]] (a declining peripheral blood oxygen saturation [SpO<sub>2</sub>] on [[pulse oximetry]] or a declining partial pressure of oxygen [PaO<sub>2</sub>] on [[arterial blood gas]] analysis) requiring high concentrations of supplemental oxygen (i.e., a higher [[fraction of inspired oxygen]] [FIO<sub>2</sub>]) or positive pressure ventilation (i.e., a higher [[continuous positive airway pressure]] [CPAP] or a higher [[positive end-expiratory pressure]] [PEEP]) in order to maintain acceptable blood oxygenation
*[[Tachypnea]] and [[Dyspnea|labored breathing]]
*[[Tachycardia]]
*Signs or symptoms that suggest worsening of the underlying illness


Left untreated, the [[mortality rate]] from ARDS is estimated to be upwards of 70%.<ref name="pmid11056707">{{cite journal| author=Reynolds HN, McCunn M, Borg U, Habashi N, Cottingham C, Bar-Lavi Y| title=Acute respiratory distress syndrome: estimated incidence and mortality rate in a 5 million-person population base. | journal=Crit Care | year= 1998 | volume= 2 | issue= 1 | pages= 29-34 | pmid=11056707 | doi=10.1186/cc121 | pmc=28999 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11056707  }} </ref>
===Exudative Phase===
The exudative phase typically encompasses the first 5 to 7 days of illness after exposure to one or more precipitation factors. Histopathologically, loss of integrity of the alveolar barrier results in influx of proteinaceous fluid into the air place and formation of hyaline membrane. [[Pulmonary edema]] and [[atelectasis]] with reduced [[pulmonary compliance]] ensue, leading to the development of [[pulmonary shunt]] and [[hypoxemia]]. In this phase, patients experience respiratory symptoms including [[dyspnea]], [[tachypnea]], and [[Labored breathing|increased work of breathing]] that eventually result in [[respiratory failure]] requiring ventilator support. If left untreated, approximately 70% of patients with ARDS may progress to [[mortality]].<ref>National Heart and Lung Institute. Task Force on Research in Respiratory Diseases, and National Heart and Lung Institute. Lung Program. Respiratory Diseases; Task Force Report on Problems, Research Approaches, Needs. The Lung Program, National Heart and Lung Institute. [Bethesda, Md., U.S. Dept. of Health, Education, and Welfare, National Institutes of Health] for sale by the Supt. of Docs., U.S. Govt. Print. Off., Washington, 1972. http://archive.org/details/respiratorydisea00nati.</ref> Among non-survivors, approximately 50% patients die within a week of the onset with exudative change as the predominant histopathological feature.<ref>Thille, Arnaud W., Andrés Esteban, Pilar Fernández-Segoviano, José-María Rodriguez, José-Antonio Aramburu, Patricio Vargas-Errázuriz, Ana Martín-Pellicer, José A. Lorente, and Fernando Frutos-Vivar. “Chronology of Histological Lesions in Acute Respiratory Distress Syndrome with Diffuse Alveolar Damage: A Prospective Cohort Study of Clinical Autopsies.” The Lancet. Respiratory Medicine 1, no. 5 (July 2013): 395–401. doi:10.1016/S2213-2600(13)70053-5.</ref>
 
===Proliferative Phase===
The proliferative phase generally lasts from day 7 to day 21. Histopathologically, reparative processes take place in the injured alveoli, including organization of exudates, a shift to [[lymphocyte]]-predominant infiltrates, and proliferation of type II [[pneumocyte]]s. In this phase, patients may recover from acute respiratory distress despite the persistence of residual symptoms. Patients who do not recover during this phase develop progressive lung injury and early changes of [[fibrosis]].
 
===Fibrotic Phase===
The fibrotic phase occurs 3 to 4 weeks following the initial pulmonary insult. Histopathologically, extensive [[fibrosis]] is prominent in the alveolar interstitium and duct, with disruption of acinar architecture and [[emphysema]]-like changes. The evidence for [[pulmonary fibrosis]] on biopsy is associated with increased [[mortality]].


==Complications==
==Complications==
[[Complications|Long-term sequelae]] of ARDS are common, however, they are more likely to develop among those who do not receive early or adequate treatment. They include:
Complications of ARDS are more likely to develop among patients who do not receive early or adequate treatment.
*Significant [[weakness]] due to [[muscle atrophy|critical illness myoneuropathy and muscle atrophy]] as a result of long-term immobilization, sometimes resulting in lifelong physical disability
 
Common complications include:
* [[Ventilator-associated pneumonia|Ventilator-associated pneumonia (VAP)]]
:* ARDS is complicated by VAP in approximately 37% to 60% of cases.<ref>Delclaux, C., E. Roupie, F. Blot, L. Brochard, F. Lemaire, and C. Brun-Buisson. “Lower Respiratory Tract Colonization and Infection during Severe Acute Respiratory Distress Syndrome: Incidence and Diagnosis.” American Journal of Respiratory and Critical Care Medicine 156, no. 4 Pt 1 (October 1997): 1092–98. doi:10.1164/ajrccm.156.4.9701065.</ref><ref>Markowicz, P., M. Wolff, K. Djedaïni, Y. Cohen, J. Chastre, C. Delclaux, J. Merrer, et al. “Multicenter Prospective Study of Ventilator-Associated Pneumonia during Acute Respiratory Distress Syndrome. Incidence, Prognosis, and Risk Factors. ARDS Study Group.” American Journal of Respiratory and Critical Care Medicine 161, no. 6 (June 2000): 1942–48. doi:10.1164/ajrccm.161.6.9909122.</ref><ref>Meduri, G. U., R. C. Reddy, T. Stanley, and F. El-Zeky. “Pneumonia in Acute Respiratory Distress Syndrome. A Prospective Evaluation of Bilateral Bronchoscopic Sampling.” American Journal of Respiratory and Critical Care Medicine 158, no. 3 (September 1998): 870–75. doi:10.1164/ajrccm.158.3.9706112.</ref><ref>Chastre, J., J. L. Trouillet, A. Vuagnat, M. L. Joly-Guillou, H. Clavier, M. C. Dombret, and C. Gibert. “Nosocomial Pneumonia in Patients with Acute Respiratory Distress Syndrome.” American Journal of Respiratory and Critical Care Medicine 157, no. 4 Pt 1 (April 1998): 1165–72. doi:10.1164/ajrccm.157.4.9708057.</ref>
:* [[VAP]] usually develops 5 to 7 days after the initial exposure to the precipitating factor.<ref>Delclaux, C., E. Roupie, F. Blot, L. Brochard, F. Lemaire, and C. Brun-Buisson. “Lower Respiratory Tract Colonization and Infection during Severe Acute Respiratory Distress Syndrome: Incidence and Diagnosis.” American Journal of Respiratory and Critical Care Medicine 156, no. 4 Pt 1 (October 1997): 1092–98. doi:10.1164/ajrccm.156.4.9701065.</ref>
:* The most likely microorganisms of [[VAP]] include non-fermenting [[Gram-negative bacilli]], [[methicillin]]-resistant ''[[Staphylococcus aureus]]'', and ''[[Enterobacteriaceae]]''.<ref>Chastre, J., J. L. Trouillet, A. Vuagnat, M. L. Joly-Guillou, H. Clavier, M. C. Dombret, and C. Gibert. “Nosocomial Pneumonia in Patients with Acute Respiratory Distress Syndrome.” American Journal of Respiratory and Critical Care Medicine 157, no. 4 Pt 1 (April 1998): 1165–72. doi:10.1164/ajrccm.157.4.9708057.</ref>
* [[Barotrauma]] (e.g., [[pneumothorax]], [[pneumomediastinum]], and [[subcutaneous emphysema]])
:* [[Barotrauma]] occurs as a consequence of inappropriate [[positive airway pressure]] in regions with reduced [[pulmonary compliance]] and may complicate ARDS in approximately 10% of cases.<ref>“Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome. The Acute Respiratory Distress Syndrome Network.” The New England Journal of Medicine 342, no. 18 (May 4, 2000): 1301–8. doi:10.1056/NEJM200005043421801.</ref><ref>Weg, J. G., A. Anzueto, R. A. Balk, H. P. Wiedemann, E. N. Pattishall, M. A. Schork, and L. A. Wagner. “The Relation of Pneumothorax and Other Air Leaks to Mortality in the Acute Respiratory Distress Syndrome.” The New England Journal of Medicine 338, no. 6 (February 5, 1998): 341–46. doi:10.1056/NEJM199802053380601.</ref><ref>Stewart, T. E., M. O. Meade, D. J. Cook, J. T. Granton, R. V. Hodder, S. E. Lapinsky, C. D. Mazer, et al. “Evaluation of a Ventilation Strategy to Prevent Barotrauma in Patients at High Risk for Acute Respiratory Distress Syndrome. Pressure- and Volume-Limited Ventilation Strategy Group.” The New England Journal of Medicine 338, no. 6 (February 5, 1998): 355–61. doi:10.1056/NEJM199802053380603.</ref>
Other complications include:
*Significant [[weakness]] due to [[muscle atrophy|critical illness myoneuropathy and muscle atrophy]] as a result of long-term immobilization
*Impaired [[Spirometry|lung function]]
*Impaired [[Spirometry|lung function]]
*Chronic [[Mechanical ventilation|ventilator dependency]] due to advanced weakness and [[atrophy]] of the [[muscles of respiration]]
*Chronic [[Mechanical ventilation|ventilator dependency]] due to advanced weakness and [[atrophy]] of the [[muscles of respiration]]
*[[Fibrotic lung disease|Pulmonary fibrosis]] and [[restrictive lung disease]]
*[[Pulmonary fibrosis]] and [[restrictive lung disease]]
*[[Psychiatric illness]] (e.g., [[post-traumatic stress disorder]] [PTSD], [[anxiety]], [[depression]])
*[[Psychiatric illness]], including [[post-traumatic stress disorder]] (PTSD), [[anxiety]], and [[depression]]
*Impaired [[cognition]]
*Impaired [[cognition]]
*[[Persistent vegetative state]] or [[brain death]] due to prolonged hypoxemia
*[[Persistent vegetative state]] or [[brain death]] due to prolonged [[hypoxemia]]


The most common complications of ARDS are those associated with a prolonged [[ICU]] stay:
Complications associated with a prolonged ICU stay include:
*[[Nosocomial infection|Secondary or nosocomial infections]] (e.g., [[hospital-acquired pneumonia|ventilator-associated pneumonia]] [VAP] or [[Intravascular device related infections|central line-associated blood stream infection]] [CLABSI])
*[[Nosocomial infection|Secondary or nosocomial infections]] (e.g., [[hospital-acquired pneumonia|ventilator-associated pneumonia]] <nowiki>[</nowiki>VAP<nowiki>]</nowiki> or [[Intravascular device related infections|central line-associated blood stream infection]] <nowiki>[</nowiki>CLABSI<nowiki>]</nowiki>)
*[[Venous thromboembolism|Venous thromboembolic events]] (e.g., [[deep vein thrombosis]] [DVT] or [[pulmonary embolism]] [PE])
*[[Venous thromboembolism|Venous thromboembolic events]] (e.g., [[deep vein thrombosis]] <nowiki>[</nowiki>DVT<nowiki>]</nowiki> or [[pulmonary embolism]] <nowiki>[</nowiki>PE<nowiki>]</nowiki>)
*[[GI bleed|Gastrointestinal bleeding]] (often secondary to [[Stress ulcer|stress ulcers]])
*[[GI bleed|Gastrointestinal bleeding]] (often secondary to [[Stress ulcer|stress ulcers]])
*[[Pressure ulcers]] and poor [[wound healing]]
*[[Pressure ulcers]] and poor [[wound healing]]
*[[Muscle atrophy|Muscle wasting]] and atrophy
*[[Muscle atrophy|Muscle wasting]] and [[atrophy]]


==Prognosis==
==Prognosis==
Prognosis for patients with ARDS varies based on the [[Acute respiratory distress syndrome diagnostic criteria|severity of illness]], the [[Acute respiratory distress syndrome causes|precipitating insult}}, and [[Acute respiratory distress syndrome risk actors|medical comorbidities]]:
Prognosis for patients with ARDS is generally poor and varies based on the severity of illness, the precipitating insult, and medical comorbidities:<ref name="pmid11056707">{{cite journal| author=Reynolds HN, McCunn M, Borg U, Habashi N, Cottingham C, Bar-Lavi Y| title=Acute respiratory distress syndrome: estimated incidence and mortality rate in a 5 million-person population base. | journal=Crit Care | year= 1998 | volume= 2 | issue= 1 | pages= 29-34 | pmid=11056707 | doi=10.1186/cc121 | pmc=28999 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11056707  }} </ref><ref name="pmid22797452">{{cite journal| author=ARDS Definition Task Force. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E et al.| title=Acute respiratory distress syndrome: the Berlin Definition. | journal=JAMA | year= 2012 | volume= 307 | issue= 23 | pages= 2526-33 | pmid=22797452 | doi=10.1001/jama.2012.5669 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22797452  }} </ref><ref name="pmid12594312">{{cite journal| author=Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al-Saidi F et al.| title=One-year outcomes in survivors of the acute respiratory distress syndrome. | journal=N Engl J Med | year= 2003 | volume= 348 | issue= 8 | pages= 683-93 | pmid=12594312 | doi=10.1056/NEJMoa022450 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12594312  }} </ref><ref name="pmid20384998">{{cite journal| author=Linko R, Suojaranta-Ylinen R, Karlsson S, Ruokonen E, Varpula T, Pettilä V et al.| title=One-year mortality, quality of life and predicted life-time cost-utility in critically ill patients with acute respiratory failure. | journal=Crit Care | year= 2010 | volume= 14 | issue= 2 | pages= R60 | pmid=20384998 | doi=10.1186/cc8957 | pmc=2887181 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20384998  }} </ref><ref name="pmid24435201">{{cite journal| author=Wang CY, Calfee CS, Paul DW, Janz DR, May AK, Zhuo H et al.| title=One-year mortality and predictors of death among hospital survivors of acute respiratory distress syndrome. | journal=Intensive Care Med | year= 2014 | volume= 40 | issue= 3 | pages= 388-96 | pmid=24435201 | doi=10.1007/s00134-013-3186-3 | pmc=3943651 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24435201  }} </ref><ref name="pmid20507948">{{cite journal| author=Sheu CC, Gong MN, Zhai R, Chen F, Bajwa EK, Clardy PF et al.| title=Clinical characteristics and outcomes of sepsis-related vs non-sepsis-related ARDS. | journal=Chest | year= 2010 | volume= 138 | issue= 3 | pages= 559-67 | pmid=20507948 | doi=10.1378/chest.09-2933 | pmc=2940067 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20507948  }} </ref>
*The [[Acute respiratory distress syndrome historical perspective|ARDS Definition Task Force]] calculated 90-day morality rates for mild, moderate, and severe ARDS as 27%, 32%, and 45%, respectively<ref name="pmid22797452">{{cite journal| author=ARDS Definition Task Force. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E et al.| title=Acute respiratory distress syndrome: the Berlin Definition. | journal=JAMA | year= 2012 | volume= 307 | issue= 23 | pages= 2526-33 | pmid=22797452 | doi=10.1001/jama.2012.5669 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22797452  }} </ref>
* The 90-day morality rates for mild, moderate, and severe ARDS are 27%, 32%, and 45%, respectively.
*The 1-year mortality rate for patients with ARDS who survive to hospital discharge varies widely between different studies and is estimated to be anywhere from 11% to over 40%<ref name="pmid12594312">{{cite journal| author=Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al-Saidi F et al.| title=One-year outcomes in survivors of the acute respiratory distress syndrome. | journal=N Engl J Med | year= 2003 | volume= 348 | issue= 8 | pages= 683-93 | pmid=12594312 | doi=10.1056/NEJMoa022450 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12594312  }} </ref><ref name="pmid20384998">{{cite journal| author=Linko R, Suojaranta-Ylinen R, Karlsson S, Ruokonen E, Varpula T, Pettilä V et al.| title=One-year mortality, quality of life and predicted life-time cost-utility in critically ill patients with acute respiratory failure. | journal=Crit Care | year= 2010 | volume= 14 | issue= 2 | pages= R60 | pmid=20384998 | doi=10.1186/cc8957 | pmc=2887181 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20384998  }} </ref><ref name="pmid24435201">{{cite journal| author=Wang CY, Calfee CS, Paul DW, Janz DR, May AK, Zhuo H et al.| title=One-year mortality and predictors of death among hospital survivors of acute respiratory distress syndrome. | journal=Intensive Care Med | year= 2014 | volume= 40 | issue= 3 | pages= 388-96 | pmid=24435201 | doi=10.1007/s00134-013-3186-3 | pmc=3943651 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24435201  }} </ref>
* The 1-year mortality rate for patients with ARDS who survive to hospital discharge varies widely and is estimated at 11% to over 40%.
*One study of patients diagnosed with ARDS in Maryland, United States, from 1992 through 1995 calculated an in-hospital mortality rate of 36% to 52%<ref name="pmid11056707">{{cite journal| author=Reynolds HN, McCunn M, Borg U, Habashi N, Cottingham C, Bar-Lavi Y| title=Acute respiratory distress syndrome: estimated incidence and mortality rate in a 5 million-person population base. | journal=Crit Care | year= 1998 | volume= 2 | issue= 1 | pages= 29-34 | pmid=11056707 | doi=10.1186/cc121 | pmc=28999 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11056707  }} </ref>
* Between 1992 and 1995, in-hospital mortality rate ranges from 36% to 52%.
*The mortality rate among patients with ARDS due to [[trauma]] appears to be lower than among patients with ARDS due to [[sepsis]]<ref name="pmid20507948">{{cite journal| author=Sheu CC, Gong MN, Zhai R, Chen F, Bajwa EK, Clardy PF et al.| title=Clinical characteristics and outcomes of sepsis-related vs non-sepsis-related ARDS. | journal=Chest | year= 2010 | volume= 138 | issue= 3 | pages= 559-67 | pmid=20507948 | doi=10.1378/chest.09-2933 | pmc=2940067 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20507948  }} </ref>
* ARDS among [[trauma]] patients have a lower mortality as compared with [[sepsis]] patients.


==References==
==References==
Line 42: Line 55:


[[Category:Pulmonology]]
[[Category:Pulmonology]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Latest revision as of 17:30, 15 July 2016

Acute respiratory distress syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acute respiratory distress syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Diagnostic study of choice

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Mechanical Ventilation Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute respiratory distress syndrome natural history, complications, and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute respiratory distress syndrome natural history, complications, and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute respiratory distress syndrome natural history, complications, and prognosis

CDC on Acute respiratory distress syndrome natural history, complications, and prognosis

Acute respiratory distress syndrome natural history, complications, and prognosis in the news

Blogs on Acute respiratory distress syndrome natural history, complications, and prognosis

Directions to Hospitals Treating Acute respiratory distress syndrome

Risk calculators and risk factors for Acute respiratory distress syndrome natural history, complications, and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Brian Shaller, M.D. [2]

Overview

If left untreated, 70% of patients with ARDS may progress to mortality. Common complications to ARDS include weakness, impaired lung function, and brain death. Prognosis for patients with ARDS is generally poor and varies based on the severity of illness, the precipitating insult, and medical comorbidities.

Natural History

The natural history of ARDS is hallmarked by three histopathological phases—exudative, proliferative, and fibrotic phase—each correlated to distinctive clinical manifestations.[1]

Exudative Phase

The exudative phase typically encompasses the first 5 to 7 days of illness after exposure to one or more precipitation factors. Histopathologically, loss of integrity of the alveolar barrier results in influx of proteinaceous fluid into the air place and formation of hyaline membrane. Pulmonary edema and atelectasis with reduced pulmonary compliance ensue, leading to the development of pulmonary shunt and hypoxemia. In this phase, patients experience respiratory symptoms including dyspnea, tachypnea, and increased work of breathing that eventually result in respiratory failure requiring ventilator support. If left untreated, approximately 70% of patients with ARDS may progress to mortality.[2] Among non-survivors, approximately 50% patients die within a week of the onset with exudative change as the predominant histopathological feature.[3]

Proliferative Phase

The proliferative phase generally lasts from day 7 to day 21. Histopathologically, reparative processes take place in the injured alveoli, including organization of exudates, a shift to lymphocyte-predominant infiltrates, and proliferation of type II pneumocytes. In this phase, patients may recover from acute respiratory distress despite the persistence of residual symptoms. Patients who do not recover during this phase develop progressive lung injury and early changes of fibrosis.

Fibrotic Phase

The fibrotic phase occurs 3 to 4 weeks following the initial pulmonary insult. Histopathologically, extensive fibrosis is prominent in the alveolar interstitium and duct, with disruption of acinar architecture and emphysema-like changes. The evidence for pulmonary fibrosis on biopsy is associated with increased mortality.

Complications

Complications of ARDS are more likely to develop among patients who do not receive early or adequate treatment.

Common complications include:

Other complications include:

Complications associated with a prolonged ICU stay include:

Prognosis

Prognosis for patients with ARDS is generally poor and varies based on the severity of illness, the precipitating insult, and medical comorbidities:[13][14][15][16][17][18]

  • The 90-day morality rates for mild, moderate, and severe ARDS are 27%, 32%, and 45%, respectively.
  • The 1-year mortality rate for patients with ARDS who survive to hospital discharge varies widely and is estimated at 11% to over 40%.
  • Between 1992 and 1995, in-hospital mortality rate ranges from 36% to 52%.
  • ARDS among trauma patients have a lower mortality as compared with sepsis patients.

References

  1. ↑ Ware, Lorraine B. “Autopsy in ARDS: Insights into Natural History.” The Lancet. Respiratory Medicine 1, no. 5 (July 2013): 352–54. doi:10.1016/S2213-2600(13)70093-6.
  2. ↑ National Heart and Lung Institute. Task Force on Research in Respiratory Diseases, and National Heart and Lung Institute. Lung Program. Respiratory Diseases; Task Force Report on Problems, Research Approaches, Needs. The Lung Program, National Heart and Lung Institute. [Bethesda, Md., U.S. Dept. of Health, Education, and Welfare, National Institutes of Health] for sale by the Supt. of Docs., U.S. Govt. Print. Off., Washington, 1972. http://archive.org/details/respiratorydisea00nati.
  3. ↑ Thille, Arnaud W., Andrés Esteban, Pilar Fernández-Segoviano, José-María Rodriguez, José-Antonio Aramburu, Patricio Vargas-Errázuriz, Ana Martín-Pellicer, José A. Lorente, and Fernando Frutos-Vivar. “Chronology of Histological Lesions in Acute Respiratory Distress Syndrome with Diffuse Alveolar Damage: A Prospective Cohort Study of Clinical Autopsies.” The Lancet. Respiratory Medicine 1, no. 5 (July 2013): 395–401. doi:10.1016/S2213-2600(13)70053-5.
  4. ↑ Delclaux, C., E. Roupie, F. Blot, L. Brochard, F. Lemaire, and C. Brun-Buisson. “Lower Respiratory Tract Colonization and Infection during Severe Acute Respiratory Distress Syndrome: Incidence and Diagnosis.” American Journal of Respiratory and Critical Care Medicine 156, no. 4 Pt 1 (October 1997): 1092–98. doi:10.1164/ajrccm.156.4.9701065.
  5. ↑ Markowicz, P., M. Wolff, K. Djedaïni, Y. Cohen, J. Chastre, C. Delclaux, J. Merrer, et al. “Multicenter Prospective Study of Ventilator-Associated Pneumonia during Acute Respiratory Distress Syndrome. Incidence, Prognosis, and Risk Factors. ARDS Study Group.” American Journal of Respiratory and Critical Care Medicine 161, no. 6 (June 2000): 1942–48. doi:10.1164/ajrccm.161.6.9909122.
  6. ↑ Meduri, G. U., R. C. Reddy, T. Stanley, and F. El-Zeky. “Pneumonia in Acute Respiratory Distress Syndrome. A Prospective Evaluation of Bilateral Bronchoscopic Sampling.” American Journal of Respiratory and Critical Care Medicine 158, no. 3 (September 1998): 870–75. doi:10.1164/ajrccm.158.3.9706112.
  7. ↑ Chastre, J., J. L. Trouillet, A. Vuagnat, M. L. Joly-Guillou, H. Clavier, M. C. Dombret, and C. Gibert. “Nosocomial Pneumonia in Patients with Acute Respiratory Distress Syndrome.” American Journal of Respiratory and Critical Care Medicine 157, no. 4 Pt 1 (April 1998): 1165–72. doi:10.1164/ajrccm.157.4.9708057.
  8. ↑ Delclaux, C., E. Roupie, F. Blot, L. Brochard, F. Lemaire, and C. Brun-Buisson. “Lower Respiratory Tract Colonization and Infection during Severe Acute Respiratory Distress Syndrome: Incidence and Diagnosis.” American Journal of Respiratory and Critical Care Medicine 156, no. 4 Pt 1 (October 1997): 1092–98. doi:10.1164/ajrccm.156.4.9701065.
  9. ↑ Chastre, J., J. L. Trouillet, A. Vuagnat, M. L. Joly-Guillou, H. Clavier, M. C. Dombret, and C. Gibert. “Nosocomial Pneumonia in Patients with Acute Respiratory Distress Syndrome.” American Journal of Respiratory and Critical Care Medicine 157, no. 4 Pt 1 (April 1998): 1165–72. doi:10.1164/ajrccm.157.4.9708057.
  10. ↑ “Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome. The Acute Respiratory Distress Syndrome Network.” The New England Journal of Medicine 342, no. 18 (May 4, 2000): 1301–8. doi:10.1056/NEJM200005043421801.
  11. ↑ Weg, J. G., A. Anzueto, R. A. Balk, H. P. Wiedemann, E. N. Pattishall, M. A. Schork, and L. A. Wagner. “The Relation of Pneumothorax and Other Air Leaks to Mortality in the Acute Respiratory Distress Syndrome.” The New England Journal of Medicine 338, no. 6 (February 5, 1998): 341–46. doi:10.1056/NEJM199802053380601.
  12. ↑ Stewart, T. E., M. O. Meade, D. J. Cook, J. T. Granton, R. V. Hodder, S. E. Lapinsky, C. D. Mazer, et al. “Evaluation of a Ventilation Strategy to Prevent Barotrauma in Patients at High Risk for Acute Respiratory Distress Syndrome. Pressure- and Volume-Limited Ventilation Strategy Group.” The New England Journal of Medicine 338, no. 6 (February 5, 1998): 355–61. doi:10.1056/NEJM199802053380603.
  13. ↑ Reynolds HN, McCunn M, Borg U, Habashi N, Cottingham C, Bar-Lavi Y (1998). "Acute respiratory distress syndrome: estimated incidence and mortality rate in a 5 million-person population base". Crit Care. 2 (1): 29–34. doi:10.1186/cc121. PMC 28999. PMID 11056707.
  14. ↑ ARDS Definition Task Force. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E; et al. (2012). "Acute respiratory distress syndrome: the Berlin Definition". JAMA. 307 (23): 2526–33. doi:10.1001/jama.2012.5669. PMID 22797452.
  15. ↑ Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al-Saidi F; et al. (2003). "One-year outcomes in survivors of the acute respiratory distress syndrome". N Engl J Med. 348 (8): 683–93. doi:10.1056/NEJMoa022450. PMID 12594312.
  16. ↑ Linko R, Suojaranta-Ylinen R, Karlsson S, Ruokonen E, Varpula T, Pettilä V; et al. (2010). "One-year mortality, quality of life and predicted life-time cost-utility in critically ill patients with acute respiratory failure". Crit Care. 14 (2): R60. doi:10.1186/cc8957. PMC 2887181. PMID 20384998.
  17. ↑ Wang CY, Calfee CS, Paul DW, Janz DR, May AK, Zhuo H; et al. (2014). "One-year mortality and predictors of death among hospital survivors of acute respiratory distress syndrome". Intensive Care Med. 40 (3): 388–96. doi:10.1007/s00134-013-3186-3. PMC 3943651. PMID 24435201.
  18. ↑ Sheu CC, Gong MN, Zhai R, Chen F, Bajwa EK, Clardy PF; et al. (2010). "Clinical characteristics and outcomes of sepsis-related vs non-sepsis-related ARDS". Chest. 138 (3): 559–67. doi:10.1378/chest.09-2933. PMC 2940067. PMID 20507948.
Retrieved from "https://www.wikidoc.org/index.php?title=Acute_respiratory_distress_syndrome_natural_history,_complications,_and_prognosis&oldid=1241844"